Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer (2018)

Peer-Reviewed Study · Sathianathen NJ, Philippou YA, Kuntz GM, et al. (Cochrane Database Syst Rev 2018;10(10):CD012816) · October 15, 2018

Sathianathen NJ et al., 2018-10-15: Cochrane review of adding taxane chemotherapy to androgen deprivation therapy within 120 days of starting ADT in metastatic hormone-sensitive prostate cancer. It finds probable overall and disease-specific survival gain, some increase in toxicity, and only a small quality-of-life benefit at 12 months.

Compared to ADT alone, the early (within 120 days of beginning ADT) addition of taxane-based chemotherapy to ADT for hormone-sensitive prostate cancer probably prolongs both overall and disease-specific survival

Abstract (AUTHORS' CONCLUSIONS)

Sathianathen NJ et al., 2018-10-15: Cochrane review of adding taxane chemotherapy to androgen deprivation therapy within 120 days of starting ADT in metastatic hormone-sensitive prostate cancer. It finds probable overall and disease-specific survival gain, some increase in toxicity, and only a small quality-of-life benefit at 12 months. Funder: internal – University of Minnesota Department of Urology (partial salary support for the first author); 'No sources of support supplied' external. Conflicts: all authors 'none known'. Drug: docetaxel (trials: CHAARTED, STAMPEDE, GETUG-AFU 15); maker not named. Comparator: ADT alone. Certainty language ('probably') is the authors'. PMC6516883. Study type: review.